Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ANIX
- Price
- 2.88
- Stock movement down
- -0.04 (-1.37%)
- Company name
- Anixa Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 96.13M
- Ent value
- 97.02M
- Price/Sales
- -
- Price/Book
- 6.89
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -5.80%
- 1 year return (CAGR)
- -8.28%
- 3 year return (CAGR)
- -12.23%
- 5 year return (CAGR)
- -11.48%
- 10 year return (CAGR)
- -0.07%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ANIX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 6.89 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 33.38M |
| EPS (TTM) | -0.34 |
| FCF per share (TTM) | -0.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -27.00K |
| Operating income (TTM) | -11.70M |
| Net income (TTM) | -10.93M |
| EPS (TTM) | -0.34 |
| EPS (1y forward) | -0.37 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.24M |
| Net receivables | 0.00 |
| Total current assets | 15.89M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 193.00K |
| Total assets | 16.08M |
| Accounts payable | 165.00K |
| Short/Current long term debt | 204.00K |
| Total current liabilities | 1.97M |
| Total liabilities | 2.13M |
| Shareholder's equity | 13.95M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -7.17M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -7.17M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -78.33% |
| Return on Assets | -67.95% |
| Return on Invested Capital | -78.10% |
| Cash Return on Invested Capital | -51.27% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.88 |
| Daily high | 3.00 |
| Daily low | 2.84 |
| Daily Volume | 95K |
| All-time high | 242.19 |
| 1y analyst estimate | 10.75 |
| Beta | 0.49 |
| EPS (TTM) | -0.34 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 13 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ANIX | S&P500 | |
| Current price drop from All-time high | -98.81% | -1.82% |
| Highest price drop | -99.75% | -56.47% |
| Date of highest drop | 15 Aug 2017 | 9 Mar 2009 |
| Avg drop from high | -82.03% | -10.84% |
| Avg time to new high | 348 days | 12 days |
| Max time to new high | 7414 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
96.13M
Marketcap category
Small-cap
Description
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Employees
4
Website
Investor relations
-
SEC filings
CEO
Amit Kumar
Country
USA
City
San Jose
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page